0000000000515849

AUTHOR

D. Schuppan

showing 3 related works from this author

IL10 promoter haplotypes may contribute to altered cytokine expression and systemic inflammation in celiac disease

2018

Celiac disease (CD) is an autoimmune/inflammatory condition triggered by dietary gluten intake in genetically predisposed individuals. Though associations with MHC class II HLA-DQ2 or -DQ8 are the primary and necessary genetic predisposition for CD, >97% of genetically predisposed individuals never develop CD. Cytokines were measured in the serum of CD patients and controls. Possible associations with IL10 promoter variants were investigated. Cytokine expression from PBMCs was monitored in response to gluten exposure, or CD3/TCR complex stimulation in the absence or presence of recombinant IL-10. Serum cytokines varied between patients with CD at the time of diagnosis, after dietary elimina…

0301 basic medicineAdolescentGenotypeGlutensCD3medicine.medical_treatmentImmunologySystemic inflammationPolymorphism Single NucleotidePeripheral blood mononuclear celllaw.invention03 medical and health sciences0302 clinical medicinelawGenetic predispositionmedicineHumansImmunology and AllergyGenetic Predisposition to DiseaseChildPromoter Regions GeneticInflammationchemistry.chemical_classificationbiologybusiness.industryInterleukin-17GlutenInterleukin-10Celiac DiseaseInterleukin 10030104 developmental biologyCytokineHaplotypeschemistryChild PreschoolImmunologybiology.proteinRecombinant DNACytokines030211 gastroenterology & hepatologymedicine.symptombusinessClinical Immunology
researchProduct

Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.

2014

Ceruloplasmin is a member of the multicopper oxidase family that plays a major role in the transport of iron in the body. Aceruloplasminaemia (ACP) is a rare disease and is clinically identified by iron overload in liver, pancreas, brain, and other organs, and by microcytic anaemia. So far, the iron chelator deferasirox was given for therapy only up to 6 months due to side effects. Here, we describe a novel mutation leading to ACP and report for the first time a long-term therapy, that is, 2 years with deferasirox. ACP was diagnosed in 3 siblings using clinical and biochemical characteristics, HFE and ceruloplasmin mutational analysis, liver biopsy, brain-, liver-, and heart-MRI. For iron d…

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismIronClinical BiochemistryCarbohydrate metabolismBiochemistryBenzoatesEndocrinologyInsulin resistanceHepcidinInternal medicineGermanyMedicineHumansChelating Agentsbiologymedicine.diagnostic_testbusiness.industryBiochemistry (medical)DeferasiroxCeruloplasminNeurodegenerative DiseasesGeneral MedicineTriazolesmedicine.diseaseIron Metabolism DisordersMagnetic Resonance ImagingPedigreeDeferasiroxEndocrinologymedicine.anatomical_structureTreatment OutcomeLiverLiver biopsyMutationbiology.proteinFemaleChromosomes Human Pair 3businessCeruloplasminPancreasmedicine.drugRare diseaseHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
researchProduct

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis

2021

ObjectiveLiver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies.DesignIndividual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were c…

Liver CirrhosisMaleCirrhosisLIVER STIFFNESS MEASUREMENTBiopsy[SDV]Life Sciences [q-bio]biostatisticsGastroenterologyDISEASEbiostatistics; clinical decision making; fatty liver; hepatic fibrosis0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosishepatic fibrosis2. Zero hunger0303 health sciencesmedicine.diagnostic_testNONALCOHOLIC STEATOHEPATITISTRANSIENT ELASTOGRAPHYFatty liverGastroenterologyCHRONIC HEPATITISMiddle Aged3. Good healthSettore AGR/03 - Arboricoltura Generale E Coltivazioni ArboreeLiverLiver biopsyBIOPSYElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyMedian bodymedicine.medical_specialtyCONTROLLED ATTENUATION PARAMETER610 Medicine & healthclinical decision making03 medical and health sciencesInternal medicineSCOREmedicineHumansbiostatistics clinical decision making fatty liver hepatic fibrosisfatty liver030304 developmental biologyReceiver operating characteristicbusiness.industrymedicine.diseaseFibrosisDiabetes Mellitus Type 2XL PROBEbusinessHepatic fibrosisTransient elastographyBiomarkersPROSPECTIVE DERIVATIONGut : the journal of the British Society for Gastroenterology
researchProduct